

# Contents

<b>1</b>	<b>Clinical Presentation of Myeloma Bone Disease . . . . .</b>	<b>1</b>
	Rebecca Silbermann and G. David Roodman	
<b>2</b>	<b>Imaging of Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias . . . . .</b>	<b>15</b>
	Ronald C. Walker, Laurie Jones-Jackson, Twyla Bartel, Tracy Brown, and Bart Barlogie	
<b>3</b>	<b>Biochemical Markers of Bone Remodeling in Multiple Myeloma . . . . .</b>	<b>63</b>
	Evangelos Terpos	
<b>4</b>	<b>Radiation Therapy in Multiple Myeloma . . . . .</b>	<b>91</b>
	Joel S. Greenberger	
<b>5</b>	<b>Surgical Management of Bone Disease . . . . .</b>	<b>101</b>
	Mohamad A. Hussein	
<b>6</b>	<b>Bisphosphonates in the Treatment of Myeloma Bone Disease . . . .</b>	<b>117</b>
	James R. Berenson	
<b>7</b>	<b>Osteonecrosis of the Jaw . . . . .</b>	<b>133</b>
	Ashraf Badros	
<b>8</b>	<b>Murine Models of Myeloma Bone Disease: The Importance of Choice . . . . .</b>	<b>151</b>
	Peter I. Croucher, Karin Vanderkerken, Joshua Epstein, and Babatunde Oyajobi	
<b>9</b>	<b>RANK Ligand Is a Therapeutic Target in Multiple Myeloma . . .</b>	<b>169</b>
	William C. Dougall, Michelle Chaisson-Blake, Howard Yeh, and Susie Jun	
<b>10</b>	<b>Osteoclast Activation in Multiple Myeloma . . . . .</b>	<b>183</b>
	Sonia Vallet and Noopur Raje	

<b>11 Potential Role of IMiDs and Other Agents as Therapy for Myeloma Bone Disease . . . . .</b>	<b>199</b>
Suzanne Lentzsch	
<b>12 Proteasome Inhibitors and the Wnt Signaling Pathway in Myeloma Bone Disease . . . . .</b>	<b>211</b>
Claire M. Edwards and Gregory R. Mundy	
<b>13 Mechanisms Involved in Osteoblast Suppression in Multiple Myeloma . . . . .</b>	<b>231</b>
Nicola Giuliani	
<b>Index . . . . .</b>	<b>243</b>

Myeloma Bone Disease

Roodman, G.D. (Ed.)

2010, X, 252 p. 75 illus., 43 illus. in color., Hardcover

ISBN: 978-1-60761-553-8

A product of Humana Press